

LeA 34494

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:


**Listing of Claims:**

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)

LeA 34494

12. (Cancelled)

13. (Currently amended) A method for treating a disorder of perception, concentration, learning and/or memory, where said disorder of perception, concentration, learning and/or memory is a result of ~~stroke~~ or Alzheimer's disease, comprising administering to a mammal in need of such treatment an effective amount of a selective PDE 2 inhibitor which inhibits human PDE 2 more strongly than it inhibits the human cAMP PDEs 3B, 4B and 7B, and which has the general formula (I)



wherein

A=D represents N=N, N=CH or CR<sup>5</sup>=N, in which R<sup>5</sup> denotes hydrogen, methyl, ethyl or methoxy,

R<sup>1</sup> and R<sup>2</sup> represent, together with the adjacent carbon atom, hydroxymethylene or carbonyl, and

R<sup>3</sup> and R<sup>4</sup> represent independently of one another methyl, ethyl, methoxy, ethoxy or a radical of the formula SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>,


in which

R<sup>6</sup> and R<sup>7</sup> denote, independently of one another, hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>3</sub>-C<sub>7</sub>-cycloalkyl, or

R<sup>6</sup> and R<sup>7</sup> form, together with the adjacent nitrogen atom, an azetidine-1-yl, pyrrol-1-yl, piperid-1-yl, azepin-1-yl, 4-methylpiperazin-1-yl or morpholin-1-yl radical, or a pharmaceutically acceptable salt thereof.

LeA 34494

14. (Previously presented) A method for treating a disorder of perception, concentration, learning and/or memory, where said disorder of perception, concentration, learning and/or memory is a result of Parkinson's disease, comprising administering to a mammal in need of such treatment an effective amount of a selective PDE 2 inhibitor which inhibits human PDE 2 more strongly than it inhibits the human cAMP PDEs 3B, 4B and 7B, and which has the general formula (I)



wherein

A=D represents N=N, N=CH or CR<sup>5</sup>=N, in which R<sup>5</sup> denotes hydrogen, methyl, ethyl or methoxy,

R<sup>1</sup> and R<sup>2</sup> represent, together with the adjacent carbon atom, hydroxymethylene or carbonyl, and

R<sup>3</sup> and R<sup>4</sup> represent independently of one another methyl, ethyl, methoxy, ethoxy or a radical of the formula SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>,

in which

R<sup>6</sup> and R<sup>7</sup> denote, independently of one another, hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>3</sub>-C<sub>7</sub>-cycloalkyl, or

R<sup>6</sup> and R<sup>7</sup> form, together with the adjacent nitrogen atom, an azetidine-1-yl, pyrrol-1-yl, piperid-1-yl, azepin-1-yl, 4-methylpiperazin-1-yl or morpholin-1-yl radical, or a pharmaceutically acceptable salt thereof.

15. (Cancelled)

LeA 34494

16. (Cancelled)